Cisplatin, gemcitabine, and ifosfamide as weekly therapy: A feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma

Journal of Clinical Oncology

Volumn 20, Issue 13, 2002, Pages 2965-2970

  Pagliaro, Lance C ^a   Millikan, Randall E ^a   Tu, Shi Ming ^a   Williams, Dallas ^a   Daliani, Danai ^a   Papandreou, Christos N ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MAGNESIUM; MANNITOL; MESNA; METHOTREXATE; PACLITAXEL; POTASSIUM; VINBLASTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BLOOD TOXICITY; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FATIGUE; FEASIBILITY STUDY; FEMALE; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; SALVAGE THERAPY; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; PILOT PROJECTS; SALVAGE THERAPY; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 0036644840     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.114     Document Type: Article

References (24)

1. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium
2. NCCN urothelial cancer practice guidelines
3. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group trial
4. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter phase III study
5. Paclitaxel, cisplatin, and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancy
6. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma
7. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC
8. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy
9. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells
10. Gemcitabine: Preclinical pharmacology and mechanisms of action
11. Gemcitabine modulation of alkylator therapy: A phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin
12. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
13. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
14. Gemcitabine (GEM) in combination with ifosfamide (IFO) and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC): A phase II study
15. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer
16. How large should a phase II trial be?
17. Non parametric estimation from incomplete observations
18. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
19. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma
20. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
21. Response to ifosfamide and mesna: 124 Previously treated patients with metastatic or unresectable sarcoma
22. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
23. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium
24. Is 'one cycle every three or four weeks' obsolete: A critical review of dose-dense chemotherapy in solid neoplasms